No Data
Sunshine Guojian Pharmaceutical (688336): Product growth is steady, pipeline is advancing in an orderly manner
Investment highlights: Event: The company released the 2024 third quarter report, and the performance meets expectations. From Q1-Q3 2024, the company's revenue was 0.939 billion yuan (+28.6%), net income attributable to the parent company was 0.233 billion yuan (+42.2%), net of non-controlling interests.
Sunshine Guojian Pharmaceutical (688336): Performance meets expectations. IL-17 is expected to submit NDA in Q4.
Executive Summary: The overall performance meets expectations, with the gradual emergence of the impact of the core product Yisaipu's centralized procurement. Saiputing and Jiannipai continue to achieve high growth, with steady progress in the pipeline, and there is hope that 608 (IL-17 monoclonal antibody) will be submitted in Q4 24.
Sunshine Guojian Pharmaceutical's Q3 Profit Jumps 50%; Shares Fall 3%
Sansei Guojian: Third Quarter Report 2024
Sunshine Guojian Pharmaceutical (688336.SH) released its performance for the first three quarters, with a net income of 0.233 billion yuan, a year-on-year increase of 42.18%.
Sunshine Guojian Pharmaceutical (688336.SH) released the third quarter report of 2024, with revenue in the first three quarters of the company at 9....
Sunshine Guojian Pharmaceutical (688336.SH): The net income in the first three quarters was 0.233 billion yuan, an increase of 42.18% year-on-year.
On October 22, Sunshine Guojian Pharmaceutical (688336.SH) announced that the company's revenue for the first three quarters was 0.939 billion yuan, a year-on-year increase of 28.58%; the net income attributable to the shareholders of the listed company was 0.233 billion yuan, a year-on-year increase of 42.18%; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.217 billion yuan, a year-on-year increase of 44.46%; basic earnings per share was 0.38 yuan.
No Data
No Data